Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.

Team

Rahul Aras, President and CEO

Rahul Aras, Ph.D.
(Co-Founder, President and Chief Executive Officer)

is the founding CEO for Juventas Therapeutics. Dr. Aras has led the Company since its inception in 2007 and has leveraged his scientific research and business experience to lead Juventas towards commercialization of its innovative therapies. Dr. Aras has successfully transitioned Juventas’ technologies from the laboratory into mid-stage clinical trials. Prior to leading Juventas, Dr. Aras was the Director of Life Science Commercialization at Cleveland Clinic Innovations where he managed commercialization of all biotechnology and pharmaceutical related technologies developed at Cleveland Clinic. Dr. Aras has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.

Matthew Pollman

Matthew Pollman, M.D.
(Chief Medical Officer)
is a cardiologist and cardiovascular molecular biologist with over ten years of experience leading R&D initiatives in the biotechnology, diagnostics, and medical devices healthcare arenas. He is currently the Chairman of Guided Interventions, LLC, a startup company developing a product to help cardiologists better assess the physiological impact of coronary artery blockages. Prior to this latest venture, Dr. Pollman served as Founder, President and Chief Scientific Officer of CV Ingenuity, an early stage company developing a combination drug/device therapy for the treatment of cardiovascular disease, recently acquired by Covidien. Additionally, he has served as Medical Director, Research and Development, Abbott Vascular serving as principal medical and scientific strategist and advisor for the R&D pipeline and Business Development portfolios; guiding both internal and external technology investments. Prior to Abbott's acquisition of Guidant Corporation, Dr. Pollman directed their New Ventures group, a 30+ member in-house start-up incubator responsible for identifying, exploring and incubating significant new business opportunities. Dr. Pollman received his medical training at the University of California San Francisco, Stanford University and Brigham and Women's Hospital. He has served as a full-time faculty member at Harvard Medical School and Morehouse School of Medicine.

Joe Pastore

Joseph Pastore, Ph.D.
(Senior Vice President, Clinical Product Development)
oversees manufacturing, preclinical, and clinical development. He has led the team that has translated Juventas’ lead product, JVS-100, from concept through Phase II trials. He is responsible for development and implementation of clinical/regulatory strategy, internal staffing and outsourcing of clinical operations, and leading interactions with the FDA which includes the approval of multiple Investigational New Drug (IND) submissions. Previous to Juventas, he worked with Guidant Corporation (acquired by Boston Scientific) where he was responsible for translating novel cardiac therapies from concept to clinic. He managed pre-clinical, first-in-man, and Phase II clinical trials, and worked cross-functionally with business development, marketing, reimbursement, and regulatory teams to build and execute development strategies for early stage products. He received his Ph.D. in Biomedical Engineering from Case Western Reserve University.